-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.
Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.
Medtronic’s fourth-quarter revenue in the US market was US$4.
Medtronic’s 2021 fiscal year announced revenue of 30.
According to reports, net profit for the 2021 fiscal year is 3.
Reference source: Medtronic scores European approvals for 2 diabetes management devices
A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.
Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.
Medtronic’s fourth-quarter revenue in the US market was US$4.
Medtronic’s 2021 fiscal year announced revenue of 30.
117 billion U.
S.
dollars.
The reported revenue increased by 4%, and the organic growth rate was 2%, which deducted 331 million U.
S.
dollars in foreign currency translation gains.
Including the company's $15 million acquisition of Titan Spine from the Cranial & Spinal Technologies division of Neuroscience's product portfolio.
Compared with the first quarter of fiscal 2020, the company's earnings from the additional week of the first quarter are approximately $360 to 390 million.
According to reports, net profit for the 2021 fiscal year is 3.
606 billion U.
S.
dollars, equivalent to 2.
66 U.
S.
dollars per share after dilution.
The non-GAAP earnings and diluted EPS for the 2021 fiscal year were US$6.
05 billion and US$4.
44, respectively, a decrease of 3%.
According to non-GAAP, diluted earnings per share increased by 2%.
Operating cash flow for the 2021 fiscal year was US$6.
24 billion.
Free cash flow for fiscal 2021 was US$4.
885 billion, which is equivalent to a free cash flow conversion rate of 81% for non-GAAP net income.
(Sina Pharmaceutical News)
Reference source: Medtronic scores European approvals for 2 diabetes management devices